4,943 research outputs found
Competence and innovation in cardiovascular MRI: statement of the German Cardiac Society
No full textStylos kai edraiōma tēs ekklēsias, sive, Dissertatio de iustificatione hominis
No full textquam ... sub praesidio ... Ioh. Henrici Heideggeri ... placido eruditorum examini subiicit Andreas Steinerus, Vitod. author & respondens, ad diem Octobris loco horisque solitisDiss. Hohe Schule Zürich, 167
Author: Andreas Johannis Prytz
No full textAn edition of the consecration sermons in Gothenburg Cathedral 1633 by Superintendent Andreas Johannis Prytz, with introductory comments. The first sermon deals with the need for Church buildings, the second with the consecration of a new Church
We must combine conservation of nature with benefits to society. Interview by Gaby Allheilig with Andreas Heinimann on IPBES' Global Assessment Report on Biodiversity and Ecosystem Services
No full textOn 6 May 2019, the Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES) presented its report on the state of biodiversity and ecosystem services worldwide. The first such assessment since 2005, it concludes that biodiversity and ecosystem loss has reached the point where it threatens human well-being. The researchers involved recommend several urgent measures to political decision-makers. Andreas Heinimann of CDE was the one Swiss scientist who worked as a lead author on a chapter of the report
Sirtuin function in aging heart and vessels
No full textAge is the most important risk factor for metabolic alterations and cardiovascular accidents. Although class III histone deacetylases, alias Sirtuins, have been appealed as "the fountain of youth" their role in longevity control and prevention of aging-associated disease is still under debate. Indeed, several lines of evidence indicate that sirtuin activity is strictly linked to metabolism and dependent on NAD(+) synthesis both often altered as aging progresses. During aging the cardiovascular system is attacked by a variety of environmental stresses, including those determined by high blood glucose and lipid levels, or by the presence of oxidized lipoproteins which, among others, determine important oxidative stress signals. In such a milieu, heart and vessels develop a functional impairment leading to atherosclerosis, ischemia, heart insufficiency and failure. Sirtuins, which are believed to have a positive impact on cardiovascular physiology and physiopathology, are distributed in different subcellular compartments including the nucleus, the cytoplasm and the mitochondria, where they regulate expression and function of a large variety of target genes and proteins. Remarkably, experimental animal models indicate resveratrol, the first natural compound described to positively regulate the activity of sirtuins, as able to protect the endothelium and the heart exposed to a variety of stress agents. This review will focus on the regulation and function of mammalian sirtuins with special attention paid to their role as cardiovascular "defenders" giving indication of their targets of potential relevance for the development of future therapeutics. This article is part of a Special Issue entitled CV Aging
To athanaton tēs psychēs, sive, Dissertatio de animae immortalitate, ex naturae & sanae rationis lumine demonstrata
No full textquam ... sub praesidio ... Iohannis Lavateri ... publicae ac placidae disquisitioni submittit Andreas Steinerus, Vitod. author & respondens ...Dedikation an Johannes Lavater, Jacob Meyer, Joh. Jacob Schaedler und Jacob Hegner auf dem Titelbl. versoDiss. Hohe Schule Zürich, 167
Family Virtues and Social Critique: Andreas Latzko’s Anti-War Prose (1917-1918)
No full textBetween 1917 and 1918, the Austro-Hungarian author Andreas Latzko (1876-1943) wrote three separate publications against the Great War: Menschen im Krieg (1917), Friedensgericht (1918), and Der letzte Mann (published 1919). Literary historians tend to bypass these works, and the few who note them chiefly focus on the best-selling novella cycle Menschen im Krieg (1917). It is usually presented as an example of expressionist political prose, or as a mixture of social satire and aesthetic shock-tactics that chiefly remains indebted to realist traditions, albeit with occasional incursions into expressionistic styles..
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial.
Get PDFThis is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal, following peer review. The version of record: Anthony Mathur, Francisco Fernández-Avilés, Jozef Bartunek, Ann Belmans, Filippo Crea, Sheik Dowlut, Manuel Galiñanes, Marie-Claire Good, Juha Hartikainen, Christine Hauskeller, Stefan Janssens, Petr Kala, Jens Kastrup, John Martin, Philippe Menasché, Ricardo Sanz-Ruiz, Seppo Ylä-Herttuala, Andreas Zeiher, BAMI Group, The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial, European Heart Journal, ehaa651, https://doi.org/10.1093/eurheartj/ehaa651 is available online at: https://doi.org/10.1093/eurheartj/ehaa651AIMS : Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. METHODS AND RESULTS : Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. Unexpectedly low recruitment means the trial no longer qualifies as a hypothesis-testing trial, but is instead an observational study with no definitive conclusions possible from statistical analysis. In total, 375 patients were recruited: 185 patients were randomized to the treatment arm (intracoronary infusion of BM-MNCs 2-8 days after PPCI) and 190 patients to the control arm (optimal medical therapy). All-cause mortality at 2 years was 3.26% [6 deaths; 95% confidence interval (CI): 1.48-7.12%] in the BM-MNC group and 3.82% (7 deaths; 95% CI: 1.84-7.84%) in the control group. Five patients (2.7%, 95% CI: 1.0-5.9%) in the BM-MNC group and 15 patients (8.1%, CI : 4.7-12.5%) in the control group were hospitalized for heart failure during 2 years of follow-up. Neither adverse events nor serious adverse events differed between the two groups. There were no patients hospitalized for stroke in the control group and 4 (2.2%) patients hospitalized for stroke in the BM-MNC group. CONCLUSIONS : Although BAMI is the largest trial of autologous cell-based therapy in the treatment of AMI, unexpectedly low recruitment and event rates preclude any meaningful group comparisons and interpretation of the observed results
- …
